Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. / Ljungman, Per; Tridello, Gloria; Piñana, Jose Luis; Ciceri, Fabio; Sengeloev, Henrik; Kulagin, Alexander; Mielke, Stephan; Yegin, Zeynep Arzu; Collin, Matthew; Einardottir, Sigrun; Lepretre, Sophie Ducastelle; Maertens, Johan; Campos, Antonio; Metafuni, Elisabetta; Pichler, Herbert; Folber, Frantisek; Solano, Carlos; Nicholson, Emma; Yüksel, Meltem Kurt; Carlson, Kristina; Aguado, Beatriz; Besley, Caroline; Byrne, Jenny; Heras, Immaculada; Dignan, Fiona; Kröger, Nicolaus; Robin, Christine; Khan, Anjum; Lenhoff, Stig; Grassi, Anna; Dobsinska, Veronika; Miranda, Nuno; Jimenez, Maria Jose; Yonal-Hindilerden, Ipek; Wilson, Keith; Averbuch, Dina; Cesaro, Simone; Xhaard, Alienor; Knelange, Nina; Styczynski, Jan; Mikulska, Malgorzata; de la Camara, Rafael.
I: Frontiers in Immunology, Bind 14, 1125824, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
AU - Ljungman, Per
AU - Tridello, Gloria
AU - Piñana, Jose Luis
AU - Ciceri, Fabio
AU - Sengeloev, Henrik
AU - Kulagin, Alexander
AU - Mielke, Stephan
AU - Yegin, Zeynep Arzu
AU - Collin, Matthew
AU - Einardottir, Sigrun
AU - Lepretre, Sophie Ducastelle
AU - Maertens, Johan
AU - Campos, Antonio
AU - Metafuni, Elisabetta
AU - Pichler, Herbert
AU - Folber, Frantisek
AU - Solano, Carlos
AU - Nicholson, Emma
AU - Yüksel, Meltem Kurt
AU - Carlson, Kristina
AU - Aguado, Beatriz
AU - Besley, Caroline
AU - Byrne, Jenny
AU - Heras, Immaculada
AU - Dignan, Fiona
AU - Kröger, Nicolaus
AU - Robin, Christine
AU - Khan, Anjum
AU - Lenhoff, Stig
AU - Grassi, Anna
AU - Dobsinska, Veronika
AU - Miranda, Nuno
AU - Jimenez, Maria Jose
AU - Yonal-Hindilerden, Ipek
AU - Wilson, Keith
AU - Averbuch, Dina
AU - Cesaro, Simone
AU - Xhaard, Alienor
AU - Knelange, Nina
AU - Styczynski, Jan
AU - Mikulska, Malgorzata
AU - de la Camara, Rafael
N1 - Publisher Copyright: Copyright © 2023 Ljungman, Tridello, Piñana, Ciceri, Sengeloev, Kulagin, Mielke, Yegin, Collin, Einardottir, Lepretre, Maertens, Campos, Metafuni, Pichler, Folber, Solano, Nicholson, Yüksel, Carlson, Aguado, Besley, Byrne, Heras, Dignan, Kröger, Robin, Khan, Lenhoff, Grassi, Dobsinska, Miranda, Jimenez, Yonal-Hindilerden, Wilson, Averbuch, Cesaro, Xhaard, Knelange, Styczynski, Mikulska and de la Camara.
PY - 2023
Y1 - 2023
N2 - Introduction: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. Methods: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. Results: The median age was 50.3 years (min – max; 1.0 – 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min – max; 0.0 – 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 – 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 – 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022. Discussion: Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.
AB - Introduction: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. Methods: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. Results: The median age was 50.3 years (min – max; 1.0 – 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min – max; 0.0 – 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 – 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 – 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022. Discussion: Although the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.
KW - allogeneic
KW - CMV
KW - COVID-19
KW - risk factors
KW - stem cell transplantation
U2 - 10.3389/fimmu.2023.1125824
DO - 10.3389/fimmu.2023.1125824
M3 - Journal article
C2 - 36960069
AN - SCOPUS:85150496015
VL - 14
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 1125824
ER -
ID: 396802069